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Death effector domain-containing protein
induces vulnerability to cell cycle inhibition
in triple-negative breast cancer
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Patricia M. Schnepp1,2, Xuejuan Tan1,2, Lan Jiang1,2, Misha Host1,2, Longhua Sun1,2, Erin N. Howe1,2,
Junmin Wu2,3, Laurie E. Littlepage 2,3,4, Harikrishna Nakshatri 4,5 & Siyuan Zhang 1,2,3,4
Lacking targetable molecular drivers, triple-negative breast cancer (TNBC) is the most
clinically challenging subtype of breast cancer. In this study, we reveal that Death Effector
Domain-containing DNA-binding protein (DEDD), which is overexpressed in > 60%
of TNBCs, drives a mitogen-independent G1/S cell cycle transition through cytoplasm loca-
lization. The gain of cytosolic DEDD enhances cyclin D1 expression by interacting with heat
shock 71 kDa protein 8 (HSC70). Concurrently, DEDD interacts with Rb family proteins and
promotes their proteasome-mediated degradation. DEDD overexpression renders TNBCs
vulnerable to cell cycle inhibition. Patients with TNBC have been excluded from CDK 4/6
inhibitor clinical trials due to the perceived high frequency of Rb-loss in TNBCs. Interestingly,
our study demonstrated that, irrespective of Rb status, TNBCs with DEDD overexpression
exhibit a DEDD-dependent vulnerability to combinatorial treatment with CDK4/6 inhibitor
and EGFR inhibitor in vitro and in vivo. Thus, our study provided a rationale for the clinical
application of CDK4/6 inhibitor combinatorial regimens for patients with TNBC.
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Cancer is a highly heterogeneous genetic disease
1. Despite
the heterogeneous nature of the tumor, targeted anti-
cancer therapies have achieved clinical success through the
exploitation of functionally essential genomic alternations, or
tumor-speciﬁc vulnerabilities2,3. In the past decade, a compen-
dium of the conceptual frameworks explaining mechanisms of
tumor vulnerabilities has been proposed and experimentally
validated, including oncogene/non-oncogene addiction4, syn-
thetic lethality5, collateral lethality6, and synthetic essentiality7. A
successful clinical translation of cancer genome studies (e.g., The
Cancer Genome Atlas (TCGA) project)) for effective targeted
anti-cancer regimens relies on two prerequisites: (1) tumor-
speciﬁc genetic or epigenetic events that confer unique vulner-
abilities (the Achilles’ heel of cancer) to therapeutic targeting; (2)
prognostic biomarkers coupled with an accessible clinical assay
for selecting patients who will most likely respond to the targeted
therapy.
Breast cancer targeted therapies are among the most successful
examples of applying the concept of targeting tumor-speciﬁc
vulnerabilities8. Estrogen receptor (ER)-targeting agents (e.g.,
tamoxifen) and human epidermal growth factor receptor 2
(HER2)-targeting therapeutics (e.g., trastuzumab) have become
ﬁrst-line treatments for ER-positive breast cancer and HER2-
positive breast cancer, respectively. Extensive pre-clinical and
clinical studies have demonstrated that biomarker-based (e.g., ER
or HER2) patient selection for targeted therapies has led to a
signiﬁcant improvement in cancer treatment with reduced side
effects compared to traditional chemotherapies9. Despite such
clinical success, targeted therapy options for the most aggressive
breast cancer subtype, triple-negative breast cancer (TNBC),
remains limited. Because TNBC lack established therapeutic
targets (e.g., ER and HER2), non-speciﬁc chemotherapy remains
the primary treatment option for TNBC patients. TNBC exhibits
a higher level of genome instability and a distinct mutational
landscape10,11. Despite the highly heterogeneous nature of TNBC
genome landscapes, some TNBC-speciﬁc tumor vulnerabilities
are emerging as clinically translatable targets for TNBC patients.
For example, poly-ADP ribose polymerase (PARP) was identiﬁed
to have a synthetic lethal dependency on BRCA1 mutation and
has been targeted in TNBC clinical trials, ultimately resulting in
recent Food and Drug Administration (FDA) approval of PARP
inhibitors for TNBC12. Additionally, bromodomain and extra-
terminal (BET) protein13 and the pyrimidine synthesis pathway14
have shown promise to be targetable TNBC vulnerabilities.
In this study, we employed a pooled whole-genome RNA
interference (RNAi) functional screen in TNBC cells to explore
potential synthetic lethal pathways that synergize with epidermal
growth factor receptor (EGFR)/HER2 inhibitor lapatinib (LAP).
Unexpectedly, we identiﬁed death effector domain-containing
protein (DEDD) as a potential vulnerability from our screen.
Interestingly, DEDD is signiﬁcantly upregulated in >60% of
TNBC tumors. While DEDD has been known to function as a
pro-apoptotic protein in the nucleus15, we found that DEDD is
strongly expressed in the cytosol of tumor cells. Mechanistically,
cytosolic DEDD promotes G1/S cell cycle transition through
multiple mechanisms. First, DEDD interacts with heat-shock
cognate 71 kDa protein (HSC70) to enhance cyclin D1 expres-
sion. Second, overexpressed cytosolic DEDD promotes the
proteasome-mediated degradation of retinoblastoma (Rb) family
proteins to enable G1/S transition. Addicted to an accelerated G1/
S cell cycle progression, tumor cells with DEDD overexpression
exhibit an increased susceptibility to the combinatorial treatment
of cyclin-dependent kinases 4/6 (CDK4/6) and EGFR inhibitors.
Furthermore, a combinatorial regimen of CDK4/6 and EGFR
inhibitors synergistically inhibited the progression of TNBC
xenografts and patient-derived xenograft (PDX) in vivo. These
pre-clinical results provide a strong rationale to extend recently
FDA-approved CDK4/6 inhibitors to TNBC patients.
Results
DEDD upregulation confers a vulnerability to EGFR/HER2
inhibitor. While TNBC tumors express EGFR, the clinical efﬁ-
cacy of anti-EGFR therapy in TNBC is low16, suggesting the
existence of alternative survival pathways that support TNBC
proliferation under EGFR inhibition. Consistent with clinical
observations, the proliferation of TNBC cells with high EGFR
expression (Supplementary Fig. 1A) was not inhibited by EGFR/
HER2 treatment (LAP) (Supplementary Fig. 1B) despite inhibi-
tion of phosphorylated (p)-EGFR, p-Akt, and p-Erk signaling
(Supplementary Fig. 1C). Interestingly, although LAP treatment
suppressed p-EGFR and downstream p-ERK, LAP did not
effectively inhibit p-Akt at 24 h post treatment compared to 2 h of
treatment (Supplementary Fig. 1C). This observation suggests
that there is an alternative pathway that allows cells to adapt to
the inhibition of the EGFR pathway. To identify such alternative
pathways, we conducted a whole-genome loss-of-function RNAi
screen by infecting the TNBC cell line (HCC1806; basal-like
BL2 subtype) with DECIPHER Lentiviral shRNA Library Human
Module 1 (5043 gene targets, 27,500 short hairpin RNAs
(shRNAs)) followed by LAP treatment (Fig. 1a). We selected the
top 200 ranked shRNA targets, which are decreased under
the LAP treatment using the MAGeCK analysis software17.
shRNA targets with reduced presentation under the LAP treat-
ment (“drop-out” hits) were potentially critical for cell survival
(Supplementary Data 1 and Supplementary Fig. 2A), particularly
under EGFR/HER2 inhibition (Fig. 1a, b). To explore the clinical
relevance of our screening result, we further examined gene
alterations of the top 200 “drop-out” hits in breast cancer genome
studies available at cBioPortal [http://www.cbioportal.org].
Among 200 hits, three genes (DEDD, ABCB10, and UAP1) are
dysregulated (ampliﬁcation and messenger RNA (mRNA) upre-
gulation) in more than 40% of TNBC tumors (Fig. 1c) and in 20%
of all breast tumors examined (Supplementary Fig. 2B, C).
Interestingly, among the top dysregulated hits, a set of genes
(DEDD, ABCB10, UAP1, KCNJ9, and PSAT1) are located close
together on chromosome 1q23.3–42.1 (Fig. 1d) and are
co-ampliﬁed in >15% of breast tumors from 164 cancer genome
studies (Fig. 1e). Signiﬁcantly, 67% of TNBC tumors have an
upregulation of DEDD (Fig. 1c) as compared to a 35–43% dys-
regulation rate among all other breast cancer cases examined in
METABRIC and the TCGA project (Supplementary Fig. 2B-D).
Upregulation of DEDD, ABCB10, or UAP1 expression does not
predict either overall or disease-free survival in TNBC patients
who received current clinical treatment regimen (Supplementary
Fig. 2E), suggesting that the genomic gain of 1q23.3–42.1, parti-
cularly DEDD, might have a unique role in conferring resistance
to EGFR signaling inhibition. To independently validate our
screening results, we used an independent set of shRNA to target
DEDD, ABCB10, or UAP1 in multiple TNBC cell lines (Supple-
mentary Fig. 3A, B and C). Multiple ABCB10 or UAP1 shRNA
knockdowns only showed moderate effects with LAP treatment in
HCC1806 cells (Supplementary Fig. 3D, E). Furthermore,
knockdown of ABCB10 or UAP1 did not show a consistent
resensitization effect on MDA-MB-468 cells to LAP treatment
(Supplementary Fig. 3D, E). Compared to ABCB10 and UAP1,
knocking down DEDD showed the most consistent and sig-
niﬁcant effect of sensitizing TNBC cells to the LAP treatment
(Fig. 1f). Furthermore, we observed that knockdown of DEDD by
DEDD siRNAs aborted sustained Akt phosphorylation at 24 h
post treatment of LAP in TNBC cells (Supplementary Fig. 3F).
Collectively, these results demonstrated that the abnormally high
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expression of DEDD in TNBC confers resistance to anti-EGFR/
HER2 treatment.
High DEDD expression facilitates G1/S progression in TNBCs.
DEDD belongs to a large family of the death effector domain
(DED)-containing proteins. Without known enzymatic activity,
DEDD executes its biological function primarily through
protein–protein interactions via its DED domain18. Previous
studies suggested that DEDD may interact with cyclin B1,
decrease Cdk1/cyclin B1 activity, and regulate cell size during
pre-mitosis phases by facilitating the G1-phase rRNA synth-
esis19. However, most studies have focused on the capacity of
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Fig. 1 Death effector domain-containing DNA-binding protein (DEDD) upregulation confers a vulnerability to epidermal growth factor receptor/human
epidermal growth factor receptor 2 (EGFR/HER2) inhibitor. a Schematic representation of the synthetic lethal bar-coded short hairpin RNA (shRNA) drop-
out screen using triple-negative breast cancer (TNBC) cell line HCC1806 with the EGFR inhibitor lapatinib (LAP) treatment. b Bar-coded shRNAs enriched
or depleted in the LAP-treated HCC1806 cells compared with dimethyl sulfoxide (DMSO)-treated cells. The bar-coded shRNAs of the top 200 depleted
genes in LAP-treated cells were considered as drop-out hits (MAGeCK method, colored yellow). c Genetic and epigenetic alterations of the top 10 genes
among top 200 depleted genes that are upregulated in estrogen-negative/progesterone receptor-negative/HER2 (ER−/PR−/HER2) normal tumors (n=
152) found within the Cancer Genome Atlas (TCGA). d Segmented view of the copy-number changes of DEDD, ABCB10, UAP1, KCNJ9, and PSAT1 in TCGA
breast-invasive carcinoma tumors. e Genome alteration frequency plot of top 10 cancer studies with DEDD, ABCB10, UAP1, KCNJ9, and PSAT1 alterations
across 164 studies in cBioPortal. f Cell counting assay validating knockdown of DEDD sensitizes TNBC cells to LAP treatment (error bars: means ± s.e.m).
Cells were normalized to DMSO control group in each shRNA or PLKO.1 (Control) group. All quantitative data were generated from a minimum of three
replicates. P values were derived from one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test comparing different shRNAs to the
PLKO.1 group
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DEDD to promote apoptosis through partnering with other
DED-containing proteins20. Since DEDD is involved in pro-
apoptotic processes, it is thought to have tumor suppressor
activities21. Paradoxically, DEDD is aberrantly overexpressed in
TNBC (Fig. 1c–e), implying that DEDD potentially has an
essential role in TNBC development. To explore the TNBC-
speciﬁc role of DEDD, we examined DEDD expression in seven
TNBC cell lines (Fig. 2a). Knocking down DEDD led to a more
signiﬁcant inhibition of cell proliferation in TNBC cells with
high expression of DEDD (HCC38 and MDA-MB-468) than
TNBC cells with moderate DEDD expression (HCC1806)
(Fig. 2b, c), suggesting that high DEDD expression TNBC cells
are more dependent on DEDD-driven proliferative signaling.
At the transcriptome level, knocking down DEDD globally
downregulated EGFR-, AKT/MEK-, and cell cycle-associated
gene signatures (Supplementary Fig. 4, RNA-sequencing
(RNA-seq) and gene set enrichment analysis (GSEA)). To
examine the mechanisms by which DEDD overexpression
impacts cell cycle regulation, we analyzed G1/S transition with
a 5-ethynyl-2′-deoxyuridine (EdU) incorporation assay. We
found that knocking down DEDD signiﬁcantly decreased EdU
incorporation in HCC38 and MDA-MB-468 TNBC cells
(Fig. 2d, e), suggesting a role of DEDD in facilitating the G1 to S
transition. To further investigate the relationship between
DEDD and cell cycle progression in TNBC, we synchronized
cell cycle progression by pretreating cells with microtubule
inhibitor nocodazole (100 ng/mL) for 18 h, and then released
cell cycle inhibition by replacing nocodazole media with a fresh
culture medium. We found that DEDD protein peaked in cells
at the G1 phase, but not other cell cycle phases (Supplementary
Fig. 5A). Further time-course cell cycle analysis suggested that
DEDD expression levels more closely correlated with cyclin D1
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Fig. 2 High death effector domain-containing DNA-binding protein (DEDD) expression facilitates G1/S progression in triple-negative breast cancers
(TNBCs). a Western blots showing the endogenous DEDD expression across multiple TNBC cell lines. b Cell counting assay showing cell relative cell
viability after DEDD knockdown in three TNBC cell lines. c Clonogenic assay showing relative colony number changes after DEDD knockdown in MDA-MB-
468 cells. d, Left: Representative images showing 5-ethynyl-2′-deoxyuridine (EdU) incorporation in TNBC cells with or without short hairpin DEDD
(shDEDD) expression. 4′,6-Diamidino-2-phenylindole (DAPI) staining (blue); EdU staining (orange). Right: Quantiﬁcation of EdU incorporation.
e Representative ﬂow biaxial plots showing cell cycle population distribution in TNBC cells with or without shDEDD expression. f Immunoblots showing
cyclin B1 and cyclin D1 expression changes with or without small interfering DEDD (siDEDD) knockdown at 0 and 9/6 h after abolishing synchronization by
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were derived from one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test comparing different shRNAs to the PLKO.1 group. Error
bars represent means ± s.e.m
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expression (Supplementary Fig. 5B-D). Consistently across
three TNBC cell lines, knocking down DEDD signiﬁcantly
decreased cyclin D1 expression, but not cyclin B1 expression
(Fig. 2f), suggesting that DEDD facilitates G1/S cell cycle
transition in TNBC through cyclin D1.
Cytosolic DEDD is sufﬁcient to facilitate G1/S transition.
DEDD nuclear localization leads to caspase activation, which
induces apoptosis, and abolishing the nuclear translocation of
DEDD decreases the apoptosis-promoting potential of the
protein15,20. Interestingly, immunohistochemistry (IHC) staining
for DEDD in TNBC tissue samples showed that DEDD primarily
localizes to the cytoplasm of tumor cells that have high DEDD
expression (Fig. 3a (left) and Supplementary Fig. 6A). Thus, we
hypothesized that overexpression of DEDD in TNBC tumor cells
has distinct tumor-promoting roles in the cytosol, which are
independent of its known nuclear function. To study the cytosol-
speciﬁc function of DEDD in promoting TNBC development, we
constructed FLAG-tagged DEDD constructs with substitution
mutations in all three previously identiﬁed nuclear localization
sequences (ΔNLS) (Fig. 3a (right) and Supplementary Fig. 6B)15.
Then, we investigated the functional impact of ectopic over-
expression of wild-type (WT) DEDD or ΔNLS-DEDD in
DEDD-diploid normal cell lines including 293FT and normal
human breast epithelial cells (HMECs) (MCF-10A, KTB-21, and
KBT-37)22. Ectopic overexpression of WT DEDD promoted G1–S
transition in 293FT cells, which could be signiﬁcantly diminished
by preventing DEDD nuclear-cytosol shuttling using nuclear
export inhibitor leptomycin (lepto) (Fig. 3b). This observation
pointed toward an essential role of cytosolic DEDD in promoting
G1/S transition. Moreover, the overexpression of cytosolic DEDD
(FLAG-ΔNLS-DEDD) was sufﬁcient to override the G1/S
checkpoint and increase the proportion of cells in S phase inde-
pendent of mitogen activation (serum starvation) as determined
by increased EdU incorporation (Fig. 3c). Additionally, after
abolishing synchronization with fetal bovine serum (FBS), there
was no difference in relation to S-phase cell proportions between
cells with DEDD overexpression and control 293FT cells (Sup-
plementary Fig. 6C). We further examined DEDD expression in
the recently established HMECs line. Compared to TNBC cell
lines, HMECs generally have very low expression of endogenous
DEDD (Supplementary Fig. 6D). Thus, HMECs provide an ideal
system to study the functional role of DEDD in cell cycle reg-
ulation. Overexpression of FLAG-ΔNLS-DEDD in KTB-21, KTB-
37, and MCF-10A cells caused a prominent increase in the pro-
portion of cells that passed through G1/S checkpoint 8 h after the
cells were released from the nocodazole synchronization (Fig. 3d,
e and Supplementary Fig. 6E). Cyclin proﬁling further revealed
that cytosolic DEDD expression in KTB-37 cells led to an accel-
erated cell cycle with induction of cyclin D1, A2, and E1
expression at 8 and 20 h post-nocodazole withdrawal (Fig. 3f).
Interestingly, KTB cells with cytosolic DEDD overexpression
appeared to be more sensitive to nocodazole-induced cell death
(Supplementary Fig. 6F), and maintained an overall higher pro-
liferation rate after nocodazole withdrawal (Supplementary
Fig. 6F, G). Together, these data imply that abnormally high
expression of cytosolic DEDD renders KTB cells more vulnerable
to cell cycle-targeting agents.
DEDD mediates HSC70-dependent G1/S progression and
cyclin D1. As an adaptor protein without known enzymatic
activities, DEDD executes its functions through protein-protein
interactions23. To explore interaction partners of DEDD in the
cytosol, we immunoprecipitated the ΔNLS-DEDD protein com-
plex and analyzed co-immunoprecipitated proteins by mass
spectrometry. Interestingly, multiple peptides representing the
HSC70 were identiﬁed (Supplementary Data 2). HSC70, also
known as HSPA8, is a member of the heat-shock protein 70
families (HSP70). Independent co-immunoprecipitation assays
further validated the interaction between DEDD and HSC70 in
both normal DEDD-diploid 293FT cells and TNBC cells (Fig. 3g
and Supplementary Fig. 6H). We next examined the necessity of
HSC70 in mediating the ΔNLS-DEDD-dependent G1/S transi-
tion. Importantly, knocking down HSC70 in two TNBC cell lines
(Supplementary Fig. 6I) and one normal cell line KTB-37
(Fig. 3h) that ectopically overexpress ΔNLS-DEDD restored the
S-phase cell cycle proﬁles to the levels seen in control cell lines
without ΔNLS-DEDD. The reduced progression through G1/S
checkpoint after HSC70 knockdown, even in the presence of
ΔNLS-DEDD, suggests that HSC70 is an essential signaling
partner for the cell cycle-promoting effect of DEDD in TNBCs. At
the molecular level, despite mitogen deprivation, overexpression
of ΔNLS-DEDD in KTB-34 and KTB-37 cells consistently
increased the baseline levels of endogenous HSC70 protein
(Fig. 3i). Also, knocking down HSC70 by small interfering RNA
concurrently reduced DEDD protein levels, particularly in cells
that overexpressed ΔNLS-DEDD (Fig. 3i). Moreover, the upre-
gulated p-Akt/Erk signaling and cyclin D1 expression that was
induced by ΔNLS-DEDD was inhibited by siHSC70 (Fig. 3i).
Cyclin D1 is an activating regulatory subunit of CDK4/6, which
are critical kinases driving G1/S transition24. Immuno-
ﬂuorescence staining conﬁrmed increased cyclin D1 expression
and a subsequent accelerated G1/S transition evidenced by
increased EdU incorporation in ΔNLS-DEDD-expressed KTB cell
lines (Fig. 3j). The above phenotypes imposed by overexpression
of ΔNLS-DEDD were completely abolished by knocking down
HSC70 (Fig. 3j and Supplementary Fig. 6I), suggesting that
HSC70 is a downstream mediator of the cell cycle-promoting
function of DEDD.
Cytosolic DEDD promotes Rb/p107 proteasome degradation.
The tumor suppressor Rb is a major component of the G1/S
checkpoint and blocks S-phase entry24. In normal cell cycle pro-
gression, mitogen-induced cyclin D partners with the CDK4/6
complex to phosphorylate Rb in G1, resulting in Rb inactivation
and de novo transcription that permits G1-to-S phase transition25.
Unexpectedly, DEDD knockdown notably increased total Rb pro-
tein levels in TNBC cells (Fig. 4a), while Rb mRNA levels either did
not change signiﬁcantly (HCC38) or decreased (HCC1806)
(Fig. 4b). This suggests that there is post-translational regulation of
Rb levels. Inhibition of protein translation by cycloheximide (CHX)
supported reduced Rb protein turnover (or increased Rb stability)
in DEDD knockdown TNBC cells at 6–12 h post treatment of CHX
(Supplementary Fig. 7A). Notably, time-dependent inhibition of
proteasome degradation machinery by MG-132 increased the total
Rb protein levels and generated a prominent higher molecular
weight smear in the control shRNA group, but not in cells with
shDEDD (Fig. 4c), suggesting that DEDD might mediate Rb post-
translational modiﬁcation via poly-ubiquitination and subsequent
proteasome-mediated degradation.
Moreover, the progressive increase of the expression of either
WT-DEDD or ΔNLS-DEDD induced a dose-dependent decrease
of Rb protein levels, whereas MG-132 treatment stabilized the Rb
protein levels in the DEDD-overexpressed cells (Fig. 4d).
Similarly, in the normal HMEC KTB cells that were not treated
with MG-132, the overexpression of ΔNLS-DEDD reduced Rb
protein expression (Fig. 4e, MG-132, 0 h). Prolonged treatment
with MG-132 (Fig. 4e, MG-132, 4–12 h) led to an accumulation of
Rb as well as FLAG-ΔNLS-DEDD. Furthermore, overexpressed
ΔNLS-DEDD co-immunoprecipitated with Rb (Fig. 4f), and
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Fig. 3 Death effector domain-containing DNA-binding protein (DEDD) mediates heat-shock cognate 71 kDa protein (HSC70)-dependent G1/S progression and
cyclin D1. a, Left: immunohistochemistry (IHC) staining of DEDD in triple-negative breast cancer (TNBC) patient-derived xenograft (PDX) tissue. Right:
Schematic of 3×-FLAG-tagged wild-type DEDD nuclear localization sequence (NLS) location and its mutated form. b, Left: Western blot showing FLAG-DEDD
expression in 293FT cells with or without cytosol shuttle inhibitor leptomycin treatment (10 μg/mL, 3 h). Right: Representative ﬂow cytometry biaxial plots of
293FT cells showing 5-ethynyl-2′-deoxyuridine (EdU) incorporation with or without expression of wild-type DEDD or cytosolic DEDD (ΔNLS-DEDD).
c Representative ﬂow cytometry biaxial plots of KTB-21 cells showing EdU incorporation with or without expression of cytosolic DEDD (ΔNLS-DEDD). DEST:
control vector. d, Left: Representative immunoﬂuorescence staining showing EdU incorporation of KTB cells with or without expression of cytosolic DEDD.
4′,6-Diamidino-2-phenylindole (DAPI): Blue; Red: EdU. Right: Quantiﬁcation of EdU incorporation assay. e Representative ﬂow cytometry biaxial plots of KTB-37
cells showing EdU incorporation with or without the expression of cytosolic DEDD after cell cycle release from nocodazole treatment (100 ng/mL) for 24 h.
f Immunoblots showing cyclin proﬁles as well as DEDD expression of control plasmid or ΔNLS-DEDD-overexpressed normal mammary epithelial cells (KTB-37)
at different time points after cells withdrawn from nocodazole treatment (100 ng/mL). g Immunoprecipitation assay showing the interaction between cytosolic
DEDD and heat- shock cognate 71 kDa protein (HSC70) after overexpressing 3×-FLAG-DEL-NLS-DEDD plasmid in 293FT cells. h Representative ﬂow cytometry
biaxial plots showing EdU incorporation of HSC70-knockdown KTB-37 cells with or without the expression of cytosolic DEDD. i Western blots showing cell
signaling changes of KTB cell lines with or without the treatment of HSC70 small interfering RNAs (siRNAs) for 2 days. j Bar chart showing the percentage of
the immunoﬂuorescence staining positive cells expressing either cytosolic DEDD or control vector in KTB cell lines with/without the treatment of
HSC70 siRNAs for 2 days. Blue: DAPI; Red: EdU+. All quantitative data were generated from a minimum of three replicates. P values were derived from one-
way analysis of variance (ANOVA) with multiple comparison test. Error bars represent means ± s.e.m.
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overexpression of ΔNLS-DEDD resulted in a signiﬁcant increase
in the poly-ubiquitination of Rb (Fig. 4g).
In addition to Rb protein, two other Rb family proteins, RBL1
(p107) and RBL2 (p130), were reported to be CDK4/6 sub-
strates26. RBL1 serves as an alternative G1/S regulator in Rb-
deﬁcient cells. We observed that overexpression of RBL1, but not
RBL2, occurred in 27% of TNBC tumors in TCGA dataset
(Supplementary Fig. 7B). Due to the structural similarity between
RB and RBL1, we further tested if DEDD also regulates
RBL1 stability through ubiquitin-mediated degradation in the
absence of Rb. In Rb-deﬁcient MDA-MB-468 cells, knockdown of
DEDD resulted in increased RBL1 (p107) expression, which
phenocopied the Rb protein expression pattern in Rb-WT TNBC
cell lines (Fig. 4h). Moreover, MG-132 treatment led to time-
dependent (0–7 h) trend in the accumulation of RBL1, which was
abolished by knocking down DEDD (Fig. 4i). We further
validated that ectopically expressed cytosolic DEDD interacted
with RBL1 and promoted its poly-ubiquitination, suggesting that
DEDD regulates RBL1 in a manner similar to Rb (Supplementary
Fig. 7C and D). Collectively, the above observations point to a
previously unknown function of cytosolic DEDD in promoting
the degradation of Rb family G1 checkpoint proteins through
ubiquitin-mediated proteasomal degradation, which subsequently
drives a mitogen-independent progression through the G1/S
transition.
CDK4/6 inhibitor synergizes with EGFR inhibitor to suppress
TNBCs. Based on the multifaceted cell cycle-promoting
mechanisms of DEDD, we hypothesized that gain-of-function
DEDD in TNBC promotes mitogen-independent G1/S transition
and confers addiction to an accelerated cell cycle program,
thereby creating a tumor-speciﬁc vulnerability for therapeutic
targeting. CDK4/6 inhibitors show signiﬁcant clinical efﬁcacy in
cancer treatment by targeting the central G1/S transition
machinery27–29. Three CDK4/6 inhibitors have recently received
FDA approval for ER+ breast cancer, including albociclib
(PALBO) (Pﬁzer, FDA 2015), ribociclib (RIBO) (Novartis, FDA
2017), and abemaciclib (ABE) (Lilly, FDA 2017). Expression of
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WT Rb, the perceived CDK4/6 downstream target, is currently
considered a prerequisite for the clinical anti-cancer efﬁcacy of
CDK4/6 inhibitors30.
Unfortunately, since Rb is frequently deleted in TNBC
tumors31, TNBC patients are excluded from CDK4/6 inhibitor
clinical trials. Interestingly, we found that targeting CDK4/6 in
combination with LAP in DEDD-overexpressed TNBC signiﬁ-
cantly and synergistically inhibited cell proliferation in both Rb-
WT (HCC38, BT-20, HCC1937, HCC1806) and Rb-deﬁcient
(MDA-MB-468) TNBC cells (Fig. 5a and Supplementary Fig. 8A,
B). This treatment phenocopied the synthetic lethality that
occurred with the loss of DEDD in conjunction with LAP
treatment (Fig. 1f). In combination with LAP, all three FDA-
approved CDK4/6 inhibitors showed consistent synergy at
fractional affected (FA) as low as 0.25 (Chou–Talalay model)32
(Fig. 5b and Supplementary Fig. 8A, B). At the molecular level,
treatment with LAP alone did not completely inhibit Akt
phosphorylation 24 h post treatment (Supplementary Fig. 8C,
and Fig. 5c). CDK4/6 inhibitor ABE alone consistently elevated
Erk phosphorylation across the four TNBC cell line tested (Fig. 5c
and Supplementary Fig. 8C). In contrast, the combination
treatment of LAP and ABE (Combo) abolished both Erk and
Akt signaling at 24 h post-Combo treatment (Fig. 5c and
Supplementary Fig. 8C).
Forkhead box M1 (FoxM1) is a transcription factor and has
been shown to be frequently upregulated in multiple cancers and
linked to sustained Akt signaling33,34. Interestingly, we observed
that FoxM1 expression was suppressed by ABE treatment in
TNBC cell lines (Fig. 5c). We next asked whether gain-of-DEDD
elicits vulnerability to Combo treatment. To determine if gain-of-
cytoplasmic DEDD expression could lead to an acquired
vulnerability to Combo treatment in normal cells, we treated
control vector and ΔNLS-DEDD-overexpressed KTB cells with
either single or Combo treatment (Fig. 5d). Ectopic expression of
cytoplasmic DEDD (ΔNLS-DEDD) rendered the KTB cells
resistant to LAP mono treatment, conﬁrming the proliferation-
driving function of cytoplasmic DEDD. Interestingly, KTB cells
with overexpressed DEDD were more responsive to CDK4/6
inhibitor treatment and Combo treatment (Fig. 5d, right). At the
molecular level, p-Akt expression is more sensitive to the
combination treatment in the ΔNLS-DEDD KTB cell lines,
determined by aberrant Akt signaling that is abolished by Combo
treatment (Fig. 5e). This further validated that cytoplasmic DEDD
(ΔNLS-DEDD) could further shift the sensitivity of TNBC cells to
combo treatment. Overexpression of ΔNLS-DEDD in MDA-MB-
436 cells, which moderately express DEDD (Fig. 2a), signiﬁcantly
enhanced sensitivity to the Combo treatment (Fig. 5f, Left),
shifting the starting FA of the synergism zone (combination index
(CI) <1) from FA= 0.5 in control vector-infected cells to FA=
0.24 in the ΔNLS-DEDD-expressed cells (Fig. 5f, right). The
increased sensitivity to Combo treatment was also evident as a
faster and more severe attenuation of p-Akt following Combo
treatment in ΔNLS-DEDD-expressed cells (Fig. 5g). To test the
long-term impact of Combo treatments on TNBC proliferation,
we compared the therapeutic efﬁcacy of Combo treatment to
mono treatment using a clonogenic assay. Combo treatment
signiﬁcantly suppressed the colony forming capability in all three
TNBC cells tested (Fig. 6a). Notably, Combo treatment reached
close to 90% inhibition of proliferation in the Rb-deﬁcient MDA-
MB-468 cells (Fig. 6a).
To translate our ﬁndings to a treatment setting, we examined
DEDD expression and localization as well as the sensitivity of
TNBC cells to Combo treatment in vivo. First, we examined
DEDD expression and localization in xenograft breast tumors
derived from two TNBC cell lines (HCC1806, MDA-MB-468)
and two TNBC PDXs(HCI-001, HCI-004) that were described
previously35. IHC analysis of DEDD showed heterogeneous but
strong DEDD expression that was localized predominately to the
cytoplasm of epithelial cells within the tumors (Fig. 6b, c). Next,
we treated the TNBC xenograft and PDX models with Combo or
mono treatment. In contrast to a single treatment, Combo
treatment signiﬁcantly decreased the size and the proliferative
index (Ki-67 IHC staining) of the tumor, and also resulted in a
moderate increase in apoptosis (cleaved caspase-3 IHC staining)
(Fig. 6d–i). A similar response to Combo treatment was also
observed in Rb-deﬁcient MDA-MB-468 xenograft tumors
(Supplementary Fig. 9A), evidenced by a moderate decrease of
Ki-67 staining and a more signiﬁcant increase of apoptosis
indicated by cleaved caspase-3 staining in the residual tumors
(Supplementary Fig. 9B,C). TNBC HCI-001 tumors were highly
resistant to LAP treatment alone and moderately responsive to
ABE (Fig. 6g), but sensitive to Combo treatment as evidenced by
signiﬁcantly reduced tumor size, reduced proliferation, and
increased apoptosis (Fig. 6h, i).
Together, these results indicate that DEDD overexpression
engages two mechanisms to achieve survival beneﬁts for cancer
cells. First, DEDD interacts with HSC70 to stabilize cyclin D1
expression. Second, DEDD promotes a poly-ubiquitin-dependent
proteasome degradation of Rb family proteins, which facilitates
G1/S transition independent of mitogen stimulation (Fig. 7).
Furthermore, blocking both EGFR/HER2 signaling and cell cycle
transition through the combinatory regimen of anti-EGFR
treatment and CDK4/6 inhibitors successfully hindered TNBC
tumor progression (Fig. 7).
Discussion
Together, our results showed that ampliﬁcation of chromosome
1q genes provides survival beneﬁts for TNBC and can be targeted
through CDK4/6 inhibitor-containing combinatorial therapies.
Our study identiﬁes DEDD as a regulator of mitogen-independent
G1/S transition in TNBC tumor cells. Through interaction with
HSC70, cytoplasmic DEDD induces cyclin D1 expression and
promotes the proteasomal degradation of Rb family members
(Fig. 7). More importantly, the gain-of-DEDD drives a previously
unknown cancer-speciﬁc vulnerability to CDK4/6 targeting
agents in combination with EGFR inhibitors, regardless of the Rb
status of the TNBC cells (Figs. 5, 6 and Supplementary Fig. 8, 9).
It has been observed for more than a decade that breast tumors
often exhibit chromosomal gains of both 1q and 8q (Fig. 1d).
Speciﬁc genes on chromosome 8q (e.g., c-MYC) have been pro-
ven to drive tumorigenesis in a broad range of human cancers36.
However, the potential chromosome 1q genes that bear functional
signiﬁcance in tumor initiation or development have not yet been
fully identiﬁed. Chromosome 1q21 ampliﬁcation is associated
with hepatocellular carcinoma, while perplexingly, both 1q dele-
tion and ampliﬁcation were reported in breast cancers37–39. The
above contradictory clinical observations suggests that a complex
and tissue-context-dependent gene function resides in the chro-
mosome 1q. Identifying such 1q genes and their associated sig-
naling cascade is crucial for developing targeted therapies tailored
towards tumors bearing 1q aberrations. Recently, Goh et al.40
reported that overexpression of S100A7/8/9 genes harbored
within 1q21.3 ampliﬁcation confers a tumor-initiating cell phe-
notype in a subset of breast cancer cells. Serving as a biomarker,
the presence of 1q21.3 ampliﬁcation in cell-free DNA from
patients’ blood strongly correlates with early breast cancer
recurrence40. Echoing the above study, we showed that the gain of
1q23.3 gene, DEDD, facilitates a mitogen-independent G1/S
transition in TNBCs (Fig. 2d, e), the most aggressive subtype of
breast cancer that frequently relapses. Although cytosol DEDD
facilitates cell cycle transition (Fig. 3), overexpression of DEDD
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Fig. 5 Cyclin-dependent kinases 4/6 (DK4/6) inhibitor synergizes with epidermal growth factor receptor (EGFR) inhibitor to suppress triple-negative
breast cancer (TNBC) proliferation. a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay showing the inhibition of cell
proliferation of TNBC cell lines treated with dimethyl sulfoxide (DMSO), lapatinib (LAP, 1 µM), abemaciclib (ABE, 0.5 µM), or Combo (LAP+ABE) for
48 h. b Drug synergism analysis showing synergism index on different FA (fraction affected) in TNBC cell lines. Dosage ratio: LAP:ABE= 4:1; LAP:RIBO
(Ribociclib)= 2:1; LAP:PALBO (Palbociclib)= 1:2. cWestern blots showing downstream signaling changes in TNBC cell lines after designated treatment for
the indicated time. d, Left: Western blots showing cytosolic DEDD expression after lentiviral infected ΔNLS-DEDD in KTB cell lines. Right: MTT assay
showing inhibition of proliferation of DEST- or ΔNLS-DEDD-expressing KTB cells treated with DMSO, LAP (0.5 µM), ABE (0.25 µM), or Combo for 48 h.
e Western blots showing EGFR, Akt, and Erk signaling changes in DEST- or ΔNLS-DEDD-expressing KTB cells treated with DMSO, LAP (0.5 µM), ABE
(0.25 µM), or Combo for 24 h. f, Left: MTT assay showing the inhibition of proliferation of MDA-MB-436 cells expressing or not expressing cytosolic DEDD
after designated treatment. Cells were treated as in d. Right: Drug synergism analysis showing synergism index on different FA with the dosage ratio of 4:1
(LAP:ABE). gWestern blots showing EGFR, Akt, and Erk signaling changes in MDA-MB-436 cells expressing or not expressing cytosolic DEDD treated with
DMSO, LAP (1 µM), ABE (0.25 µM), or Combo for indicated hours. All quantitative data were generated from a minimum of three replicates. Error bars
represent means ± s.e.m. For a, P values were derived from one-way analysis of variance (ANOVA) with multiple comparison test. For d, f, P values were
derived from two-tailed t test. n.s., not signiﬁcant
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alone was not sufﬁcient to drive normal mammary epithelial cell
(KTB cells) transformation in soft-agar assays (data not shown).
Likewise, DEDD did not inﬂuence overall survival and disease-
free survival of TNBC patients who received traditional che-
motherapies (Supplementary Fig. 2E). Thus, we deduce that
DEDD may function as a facilitator of tumor progression, instead
of a key driver in tumorigenesis.
Many proteins have distinct functions when translocated into
different subcellular compartments. One of the well-studied
examples is the tumor suppressor PTEN. In the cytosol, PTEN
suppresses the phosphoinositide 3-kinase (PI3K)/AKT pathway
through its lipid phosphatase activity, while a nuclear pool of
PTEN maintains chromosomal stability41. DEDD has been well
documented to be a nuclear-targeting protein through its three
nuclear localization sequences18. DEDD functions as an apoptosis
facilitator in the nucleus by interacting with caspase-8 and cas-
pase-10, and stimulating caspase-dependent cell death15,20,21,42.
Surprisingly, once overexpressed in TNBC cells, DEDD primarily
resides in the cytoplasm (Figs. 3a, 6b, and Supplementary
Fig. 6A), suggesting that DEDD may play different roles in the
regulation of cellular functions in the cytoplasm. In stark contrast
to the apoptosis-promoting function of DEDD in the nucleus, our
study revealed a role of cytosolic DEDD in promoting G1/S
transition that provides a pro-proliferative beneﬁt in both
KTB and TNBC cells (Fig. 3d–f and Supplementary Fig. 6).
It appears that the DEDD nuclear/cytosol equilibrium is
critical for the cellular decision of cell proliferation or cell death.
Previous studies have suggested that ubiquitination machinery
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Fig. 6 Cyclin-dependent kinases 4/6 (CDK4/6) inhibitor synergizes with epidermal growth factor receptor (EGFR) inhibitor to suppress triple-negative breast
cancer (TNBC) tumor growth. a, Top: Representative pictures of clonogenic assay showing the inhibition of tumor progression in TNBC cell lines. Bottom:
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regulates protein nuclear/cytosol shuttling. For example, mono-
ubiquitination of PTEN leads to its nuclear localization, whereas
poly-ubiquitination of PTEN favors proteasomal degradation43.
Similarly, in non-cancerous cells, DEDD exists in non-ubiquiti-
nated, monoubiquitinated, and diubiquitinated forms. Mono-
ubiquitin retains DEDD in the cytosol20. The mechanisms by
which ubiquitination machinery ﬁne-tunes the subcellular loca-
tion of DEDD and its pro- or anti-proliferative functions in the
TNBC cells warrants further study.
In our study, we demonstrated that cytosolic overexpression of
DEDD facilitates G1/S transition (Fig. 3c–g and Supplementary
Fig. 6). Since DEDD protein has not been shown to have enzy-
matic activity, it is intriguing to explore the mechanism by which
DEDD regulates cell cycle transition. Our data provided the evi-
dence that DEDD regulates G1/S cell cycle transition through
multifaceted mechanisms. First, we demonstrated that the
cell cycle-promoting function of DEDD is dependent on its cel-
lular interacting partner HSC70 (Fig. 3g–j and Supplementary
Fig. 6H, I). Previous studies have shown that DEDD, which
lacks enzymatic activity, binds to DED-containing proteins, such
as caspase-6, -8, and -10, through its DED domain15,42, a
protein–protein interaction domain only found in proteins that
are involved in apoptosis signaling44. Besides the DED domain,
no other functional domains have been identiﬁed on DEDD.
Interestingly, beyond the strictly DED-domain-mediated
protein–protein interactions, our study revealed that cytosolic
DEDD also binds to HSC70 chaperone protein in TNBC cells.
This suggests that DEDD might engage a different set of protein
binding partners to modulate cellular functions at different cell
cycle stages. Our data show that DEDD and HSC70 interact to
stabilize each other and cyclin D1, a critical component of the
G1/S regulation complex cylcin D1–CDK4/6, which is known as
one major binding substrate of HSC70 chaperone45. In addition,
we also observed that other than cyclin D1, DEDD also mediates
cyclin B1 expression in multiple TNBC cell lines (Fig. 2f), which
is consistent with previous reports demonstrating that DEDD
associates with cyclin B1 to regulate G2/M transition in mouse
ﬁbroblast cells19. Furthermore, it has been shown that DEDD
associates with and stabilizes cyclin D346. Thus, DEDD may play
multiple roles in cell cycle regulation other than G1/S transition
in TNBC.
In this study, we also discovered that cytosolic DEDD interacts
with Rb family proteins and modulates protein turnover through
ubiquitin-mediated proteasomal degradation (Fig. 4g and Sup-
plementary Fig. 7D). Previous studies of Rb regulation have been
focused on its genetic deletion or mutation, as well as altered
expression of the upstream regulators such as CDK4/625,26. In
contrast, the mechanisms that regulate Rb protein turnover are
still largely understudied. One E3 ubiquitin ligase NRBE3 has
been reported to be involved in the ubiquitin-dependent and
proteasome-dependent degradation of Rb protein in vitro47.
Another report suggests that p38 mitogen-activated protein
kinase (MAPK) phosphorylates Rb on Ser567 in response to
genotoxic stress. Hyperphosphorylation of Rb leads to its inter-
action with E3 ligases Hdm248. However, the functional relevance
of the above in relation to observations to tumorigenesis in vivo
has not been addressed. In this study, we discovered that aberrant
overexpression of DEDD greatly accelerated ubiquitination and
proteasomal degradation of Rb family proteins, including Rb
protein and Rb family protein RBL1 in TNBC cells (Fig. 4 and
Supplementary Fig. 7). Mechanistically, considering its non-
enzymatic nature, DEDD may act as an essential adaptor to
engage the ubiquitin machinery. One possible mechanism could
be that cytosolic DEDD directly recruits Rb and E3 ubiquitin
ligases simultaneously into the same protein complex, thereby
facilitating the poly-ubiquitination of Rb and subsequent pro-
teasome degradation. Another possible mechanism could be that
DEDD promotes p38 MAPK-mediated Rb hyperphosphorylation
and indirectly enhances the ubiquitination of Rb. Exploring the
above hypotheses in the TNBC context in future studies will
add important mechanistic insight to the compendium of Rb
regulation.
As discussed above, our study demonstrated that the major role
of cytosolic DEDD is to promote G1/S transition. In DEDD-
ampliﬁed TNBC cells, but not DEDD diploid cells, an accelerated
G1/S transition occurs, resulting in a “non-oncogene addiction
phenotype.” These cells are particularly sensitive to cell cycle
disruption by either knocking down DEDD or inhibiting CDK4/6
(Figs. 2b–e, 5a, b and Supplementary Fig. 8). Importantly, while
inhibition of CDK4/6 alone only suppresses tumor cell pro-
liferation to some degree in multiple TNBC cell lines (Figs. 5a,
6a–g and Supplementary Figs. 8, 9), targeting the EGFR pathway
synergizes with CDK4/6 inhibitors (abemaciclib, palbociclib,
ribomaciclib), leading to a synthetic lethal effect in both Rb-WT
and Rb-deﬁcient TNBC cells. The combination treatment of both
EGFR and CDK4/6 inhibitors effectively decreases Akt phos-
phorylation compared to EGFR inhibitor alone in responding
TNBC cell lines (Fig. 5c–g). Although LAP is effective in inhi-
biting p-Akt transiently (Supplementary Fig. 1C), TNBCs quickly
adopt a mechanism that consistently sustains Akt signaling, and
this sustained p-Akt is partially DEDD dependent (Fig. 5c and
Supplementary Figs. 1D, 3F, 8C). It has been shown that female
mice lacking DEDD are infertile owing to unsuccessful decid-
ualization, which appears to be caused by decreased Akt levels,
since polyploidization was restored in DEDD-deﬁcient decidual
cells by overexpression of Akt49. Thus, DEDD is highly involved
in maintaining Akt signaling, which is different from the cell
death signaling that has previously been well investigated. Inter-
estingly, our data demonstrated that further inhibiting CDK4/6
activity effectively abolished p-Akt (Fig. 5c and Supplementary
Fig. 8C). This observation suggests that an intriguing cross-talk
between the CDK4/6 cell cycle cascade and Akt signaling exists,
which is consistent with a recent report showing synergy between
CDK4 and HER2 inhibition in HER2+ breast tumor model50.
Mechanistically, we envision two potential mechanisms
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contributing to the observed synergy. First, previous studies have
demonstrated that cyclin D1–CDK4/6 complex down-regulates
TSC1/2 and promotes mTORC1 activation51. Since it has been
well established that the mTORC1 activation leads to PI3K and
MAPK inhibition through a negative feedback loop, upregulation
of cyclin D1 by overexpression of DEDD (Fig. 3f–j) will likely lead
to a hyper-activation of mTORC1, rendering an attenuated PI3K/
MAPK pathway activation49. The inhibition of cyclin D1–CDK4/
6 complex by CDK4/6 inhibitors phenocopies mTORC1 inhibi-
tion and unleashes the activity of the MAPK pathway. Indeed, we
observed that CDK4/6 inhibitor treatment alone increased the
ERK phosphorylation in multiple TNBC cells that overexpress
DEDD (Fig. 5c and Supplementary Fig. 8C). Adding LAP to
CDK4/6 inhibition completely abolished this negative feedback
activation of ERK 24 h post treatment (Fig. 5c and Supplementary
Fig. 8C). Second, in addition to Rb and TSC1/2, transcription
factor forkhead box M1 (FoxM1) has been identiﬁed as a CDK4/
6 substrate through a proteomics screen52. FoxM1 is a typical
proliferation-associated transcription factor that stimulates pro-
liferation by promoting S-phase and M-phase entry, and is
additionally involved in the proper execution of mitosis33. Pre-
vious reports demonstrated that FoxM1 activates the Akt pathway
via c-Met and causes resistance to tyrosine kinase inhibitors53.
Other literature shows platelet-derived growth factor subunit a
(PDGFA) is a transcription target of FoxM1, and FoxM1 pro-
motes breast cancer tumorigenesis by transcriptionally activating
PDGFA, which led to further Akt phosphorylation in breast
cancer cells54. Supporting such ﬁndings, we observed that phos-
phorylation and total expression of FoxM1 were effectively
blocked by CDK4/6 inhibitors (Fig. 5c), which can explain the
synergistic effect of applying both EGFR and CDK4/6 inhibitors
in TNBC. Future investigation of DEDD-mediated FoxM1-Akt
cross-talk will further guide rationally designed combinatorial
therapy for TNBC patients.
In summary, our study revealed a mechanism governing cell
cycle progression. While providing proliferative beneﬁt, the gain
of chromosome 1q gene DEDD also confers a DEDD-dependent
vulnerability to CDK4/6 targeting combinatorial therapies. As
CDK4/6 inhibitors are widely used in the clinic, our study pro-
vided a crucial pre-clinical rationale for a readily clinically
translatable combinatorial strategy for TNBC patients.
Methods
Chemicals and cell culture. LAP (L-4899) and palbociclib (P-7766) were pur-
chased from LC Laboratories. Abemaciclib (HY-16297), ribociclib (HY-15777),
and nocodazole (HY-13520) were purchased from MedchemExpress Inc. Lepto-
mycin B (9676S) was purchased from Cell Signaling Technology. MG-132 (80053-
196) was purchased from VWR. CHX (01810) was purchased from Sigma-Aldrich.
The 293FT (R70007) cells were purchased from Thermo Fisher Scientiﬁc Com-
pany. BT-20, BT-474, HCC1806, HCC1937, HCC38, MDA-MB-231, MDA-MB-
436, and MDA-MB-468 cell lines were obtained from ATCC (Manassas, VA,
USA). The 293FT cell line was cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) high glucose supplemented with 10% FBS and 1%
penicillin–streptomycin (Pen-Strep). BT-20, BT-474, MDA-MB-231, MDA-MB-
436, and MDA-MB-468 cell lines were cultured in DMEM/Ham’s F-12 (1:1)
supplemented with 10% FBS and 1% Pen-Strep. HCC1806, HCC1937, and HCC38
cell lines were cultured in RPMI-1640 medium supplemented with 10% FBS and
1% Pen-Strep. The MCF-10A was originally purchased from ATCC and cultured in
DMEM/F-12 medium supplemented with 5% horse serum (Invitrogen), 20 ng/mL
EGF, 10 µg/mL insulin, 0.5 µg/mL hydrocortisone, 100 ng/mL cholera toxin, and
1% Pen-Strep. Normal human mammary epithelial lines from Komen Tissue Bank
(KTB) were obtained from our collaborator Dr. Nakshatri and cultured in DMEM/
F-12 supplemented with 10% FBS, 0.4 μg/mL hydrocortisone, 5 μg/mL insulin, 20
ng/mL EGF, 24 mg/L adenine, and 5 μM ROCK (Rho-associated, coiled-coil con-
taining protein kinase) inhibitor (Y-27632). All cell lines were maintained at 37 °C
in a 5% CO2 humidiﬁed environment and subcultured upon reaching approxi-
mately 90% conﬂuence. Twenty-four hours before experiments, cells were re-plated
into new Petri dishes with fresh medium at about 50% conﬂuency. BT-20, BT-474,
HCC1806, HCC1937, HCC38, MDA-MB-231, MDA-MB-436, MDA-MB-468, and
MCF-10A were authenticated by DNA analysis by Genetica Cell Line Testing.
Lentiviral transfection assay and plasmids. Human DEDD complementary
DNA (cDNA) sequence (refGene_NM_001039711 range=
chr1:161,122,147–161,124,462) It was obtained from the UCSC Genome Browser.
DEDD coding sequence:
5′-ATGGCGGGCCTAAAGCGGCGGGCAAGCCAGGTGTGGCCAGAAGA
GCATGGTGAGCAGGAACATGGGCTGTACAGCCTGCACCGCATGTTTGAC
ATCGTGGGCACTCATCTGACACACAGAGATGTGCGCGTGCTTTCTTTCCT
CTTTGTTGATGTCATTGATGACCACGAGCGTGGACTCATCCGAAATGGA
CGTGACTTCTTATTGGCACTGGAGCGCCAGGGCCGCTGTGATGAAAGTA
ACTTTCGCCAGGTGCTGCAGCTGCTGCGCATCATCACTCGCCACGACCT
GCTGCCCTACGTCACCCTCAAGAGGAGACGGGCTGTGTGCCCTGATCTT
GTAGACAAGTATCTGGAGGAGACATCAATTCGCTATGTGACCCCCAGAG
CCCTCAGTGATCCAGAACCAAGGCCTCCCCAGCCCTCTAAAACAGTGCC
TCCCCACTATCCTGTGGTGTGTTGCCCCACTTCGGGTCCTCAGATGTGTA
GCAAGCGGCCAGCCCGAGGGAGAGCCACACTTGGGAGCCAGCGAAAAC
GCCGGAAGTCAGTGACACCAGATCCCAAGGAGAAGCAGACATGTGACA
TCAGACTGCGGGTTCGGGCTGAATACTGCCAGCATGAGACTGCTCTGCA
GGGCAATGTCTTCTCTAACAAGCAGGACCCACTTGAGCGCCAGTTTGAG
CGCTTTAACCAGGCCAACACCATCCTCAAGTCCCGGGACCTGGGCTCCA
TCATCTGTGACATCAAGTTCTCTGAGCTCACCTACCTCGATGCATTCTGG
CGTGACTACATCAATGGCTCTTTATTAGAGGCACTTAAAGGTGTCTTCAT
CACAGACTCCCTCAAGCAAGCTGTGGGCCATGAAGCCATCAAGCTGCTG
GTAAATGTAGACGAGGAGGACTATGAGCTGGGCCGACAGAAACTCCTGA
GGAACTTGATGCTGCAAGCATTGCCCTGA-3′.
DEDD DEL-NLS coding sequence:
5′-ATGGCGGGCCTAGCGGCAGCAGCAAGCCAGGTGTGGCCAGAAGA
GCATGGTGAGCAGGAACATGGGCTGTACAGCCTGCACCGCATGTTTGAC
ATCGTGGGCACTCATCTGACACACAGAGATGTGCGCGTGCTTTCTTTCC
TCTTTGTTGATGTCATTGATGACCACGAGCGTGGACTCATCCGAAATGG
ACGTGACTTCTTATTGGCACTGGAGCGCCAGGGCCGCTGTGATGAAAGT
AACTTTCGCCAGGTGCTGCAGCTGCTGCGCATCATCACTCGCCACGACC
TGCTGCCCTACGTCACCCTCAAGCTGAGACTCGCTGTGTGCCCTGATCT
TGTAGACAAGTATCTGGAGGAGACATCAATTCGCTATGTGACCCCCAGA
GCCCTCAGTGATCCAGAACCAAGGCCTCCCCAGCCCTCTAAAACAGTGC
CTCCCCACTATCCTGTGGTGTGTTGCCCCACTTCGGGTCCTCAGATGTGT
AGCAAGCGGCCAGCCCGAGGGAGAGCCACACTTGGGAGCCAGCGAATC
CTGCGGATCTCAGTGACACCAGATCCCAAGGAGAAGCAGACATGTGACA
TCAGACTGCGGGTTCGGGCTGAATACTGCCAGCATGAGACTGCTCTGCA
GGGCAATGTCTTCTCTAACAAGCAGGACCCACTTGAGCGCCAGTTTGAG
CGCTTTAACCAGGCCAACACCATCCTCAAGTCCCGGGACCTGGGCTCCA
TCATCTGTGACATCAAGTTCTCTGAGCTCACCTACCTCGATGCATTCTGG
CGTGACTACATCAATGGCTCTTTATTAGAGGCACTTAAAGGTGTCTTCAT
CACAGACTCCCTCAAGCAAGCTGTGGGCCATGAAGCCATCAAGCTGCTG
GTAAATGTAGACGAGGAGGACTATGAGCTGGGCCGACAGAAACTCCTGA
GGAACTTGATGCTGCAAGCATTGCCCTGA-3′.
Human DEDD cDNA coding sequence was cloned into lentivirus mammalian
expression vector pLOVE empty (Addgene #15948) or pLenti-CMV-puro-DEST
(Addgene #17452) with an N-terminal 3×-FLAG tag. DEDD mutant entry vector
was assembled through GeneArt Gene Synthesis (Thermo Fisher Scientiﬁc). For
lentiviral production, a lentiviral expression vector was co-transfected with second-
generation lentivirus packing vectors psPAX2 and pMD2.G (Addgene) into
293FT cells using CalFectin (SignaGen, Rockville, MD, USA). Forty-eight hours
after transfection, breast cancer cell lines were stably infected with viral particles.
pLOVE-GFP served as packaging and infection efﬁciency control. Lentiviral-based
pLKO.1 DEDD shRNA vectors were purchased from Sigma-Aldrich Co. (St. Louis,
MO, USA). The control shRNA vector (pLKO.1 scrambled shRNA) was from
Addgene Inc. (Cambridge, MA, USA).
The DEDD-targeting shRNA sequences used in the lentiviral constructs were:
shDEDD−493, 5′-CCGGGAGGAGACATCAATTCGCTATCTCGAGATAGCGA
ATTGATGTCTCCTCTTTTTTG-3′ (targeting CDs); shDEDD-867, 5′-CCGGCA
TCATCTGTGACATCAAGTTCTCGAGAACTTGATGTCACAGATGATGTTTT
TTG-3′ (targeting CDs); shDEDD1056, 5′-CCGGGAAACTCCTGAGGAACTTG
ATCTCGAGATCAAGTTCCTCAGGAGTTTCTTTTTTG-3′.
Stable expression or knockdown clones were selected by culturing cells with
puromycin (1–5 μg/mL) for at least 48 h. The uninfected cells were also treated
with puromycin as a control. Infected cells have a multiplicity of infection (MOI)
around 0.3–0.6.
Primers. Primers for constructing 3×-FLAG-DEDD or 3×-FLAG-Del-NLS-DEDD:
N-3×-FLAG-DEDD—forward primer: melting temperature (TM): 72.4℃
5′-CACCATG GAC TAC AAA GAC CAC GAC GGC GAC TAC AAA GAC
CAC GAC ATC GAC TAC AAA GAC GAT GAC GAC AAGATGGCGGGCCTA.
N-3×-FLAG-DEDD—reverse primer: TM: 72.1℃
5′-TCA GGG CAA TGC TTG CAG CAT CAA GTT CCT CAG GAG TTT
CTG TCG GCC CAG CTC ATA GTC.
Primers for detecting gene mRNA level:
DEDD—forward primer: TM: 56.6℃
5′-ATGGACGTGACTTCTTATTG-3′.
DEDD—reverse primer: TM: 56.4℃
5′-ATACTTGTCTACAAGATCAGGG-3′.
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RB1—forward primer: TM: 57.2℃
5′-CAGAAATGACTTCTACTCGAAC-3′.
RB1—reverse primer: TM: 58.9℃
5′-AATGTGGCCATAAACAGAAC-3′.
ABCB10—forward primer: TM: 62.1℃
5′-CCATATTTCAGGATTTCAGCC-3′.
ABCB10—reverse primer: TM: 54.8℃
5′-GACTAATAGTTCCAGAAGCAG-3′.
UAP1—forward primer: TM: 56.7℃
5′-GATAGTCAGAATGGGAAAGAC-3′.
UAP1—reverse primer: TM: 56.3℃
5′-GCATAGGAGATAAGAGGAGAG-3′.
Genome-wide bar-coded shRNA screening and MAGeCK analysis. In vitro
pooled drop-out screening by infect HCC1806 cells at 0.3 MOI with DECIPHER
shRNA lentiviral library (Cellecta Inc., human model 1, Cat. #DHPAC-M1-P),
which includes about 27,000 shRNA constructs targeting 5043 genes on human
signaling pathways. After 8 days of puromycin (1 µg/mL) selection, infected cells
were treated with either dimethyl sulfoxide (DMSO) or LAP (2 µM) for 14 days
with replacing fresh medium containing drug every 48 h. After 14 days of treat-
ment, the cells are collected and sent for barcodes sequencing by Illumina
sequencing. The row barcode counts were analyzed for the “drop-out” hits using
the MAGeCK software as described before17.
Cell proliferation assays. For MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide) assays, cells (3000/well) were seeded in at least triplicate in
96-well plates and treated with various concentrations of a single treatment or
combination treatment for designated times. Cell proliferation was determined by
incubating with MTT for 3 h and then in lysing buffer (50% DMF (N, N-dimethyl
formamide) (Sigma, D-4254), 10% SDS (sodium dodecyl sulfate) (Sigma, L-4509))
overnight. The 96-well plate was read at 570 nm absorbance by a microplate reader.
We used the wells with cells untreated as 100% control and the wells with only
medium as 0% control. Percentage of inhibition of cell proliferation was calculated
as [100− ((OD treated −OD empty)/(OD untreated –OD empty) × 100]. For
direct cell counting, cells (3000/well) were seeded in at least triplicate in 96-well
plates and treated with various concentrations of the single treatment or combi-
nation treatment for designated times. Cell proliferation was determined by directly
counting cell numbers in each well using hemacytometer and compared using the
wells with untreated cells as 100% control and the wells with only medium as 0%
control. For the clonogenic assay, cells were plated approximately 3000 cells/well in
24-well plates in 10% FBS. After 24 h, cells were treated in triplicate with various
concentrations of a single or combination treatment for approximately 2 weeks
with media replacement and treatment every 48 h. Cells were washed with
phosphate-buffered saline (PBS), ﬁxed, and stained with a solution containing 6%
glutaraldehyde and 0.5% crystal violet. Plates were dried, and each well was pho-
tographed and quantiﬁed using ImageJ 1.43u (National Institutes of Health,
Bethesda, MD, USA).
Quantitative RT-PCR assay. Total cell RNA will be extracted using TriZol reagent
(Invitrogen) following the manufacturer’s instructions. One microgram of total
RNA was subjected to reverse transcription to synthesize cDNA using the Verso
cDNA Kit (Thermo Fisher Scientiﬁc). A 20 μL volume reaction consisted of 2 μL
reverse transcription product and 20 nM of both forward and reverse primer. The
samples were incubated with 2× iTaq™ Universal SYBR® Green Supermix (Bio-
Rad). Relative expression levels were calculated using the 2−ΔΔCT method.
EdU incorporation assay. Twenty-four hours before the experiment, the culture
medium was replaced with medium without FBS. This would synchronize the cells
in G0. After 24-h serum starvation, the cells were treated with 1 ng/mL EGFs to
induce cell cycle reentry. Cells were treated with 10 µM of EdU for 1–6 h. Cells
were collected and processed following the protocol of either Click-iT® Plus EdU
Alexa Fluor® 488 Flow Cytometry Assay Kit or by Click-iT™ EdU Alexa Fluor™ 594
Imaging Assay. In the Click-iT® Plus EdU Alexa Fluor® 488 Flow Cytometry Assay
Kit (Thermo Fisher Scientiﬁc) plus 2 μg/mL propodium podide staining (Thermo
Fisher Scientiﬁc), cells were rehydrated in 1% bovine serum albumin-PBS at a
density of 1 × 106 cells/mL, transferred into ﬂow cytometry analysis tubes, and
stored overnight at 4 °C prior to samples analysis by Beckman Coulter FC500 Flow
Cytometer. EdU signal was detected in FL1 (515–536 nm), and PI signal was
detected in FL3 (590–615 nm). Twenty thousand events will be recorded and
analyzed using the FlowJo software. In the Click-iT™ EdU Alexa Fluor™ 594 Ima-
ging Assay, cells were mounted in ProLong™ Gold Antifade Mountant for 24 h
before imaging using the Leica ﬂuorescence microscope in HCRI Tissue Core
Facility (Notre Dame, IN, USA). All experiments were repeated three times, and
quantitative results were analyzed by one-way analysis of variance (ANOVA) or t
test, where P < 0.05 was considered statistically signiﬁcant.
Immunoprecipitation and immunoblotting assays. For immunoprecipitation,
cells ﬁrst were transfected with either empty or DEDD plasmid. Forty-eight
hours later, cells were treated with 1 ng/mL of EGF and then with 1 µM MG-132
for 6 h before collection. Harvested cells were re-suspended in 500 µL of M2 lysis
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.5 mM
EDTA). After incubation for 1 h on ice, cell lysates were incubated with 1 µg of
Rb (4H1) antibody overnight (18 h). One percent of cell lysates were saved as
input control. After that, the samples were incubated with 50 µL of protein A/G
agarose beads (Santa Cruz) for 2 h at 4 °C. Immunocomplexes were washed with
M2 lysis buffer three times before immunoblotting. For immunoblotting, pro-
teins were extracted using M2 lysis buffer and proteinase plus phosphatase
inhibitor cocktail (Cell Signaling #5872). Protein extracts were resolved using
4–20% gradient SDS-polyacrylamide gel electrophoresis gels and transferred to
nitrocellulose membranes (Thermo Fisher Scientiﬁc #88018). Membranes were
probed with primary antibodies overnight on a 4 °C shaker and then incubated
with horseradish peroxidase (HRP)-conjugated secondary antibodies. Signals
were visualized with SuperSignal West Pico Chemiluminescent Substrate
(Thermo Fisher Scientiﬁc #34078).
Antibodies. DEDD (Sc-271192) and HSC70 (sc-7298) antibodies were purchased
from Santa Cruz Biotechnology. β-Actin (ab8226) was purchased from Abcam.
FLAG M2 (F1804) was purchased from Sigma-Aldrich. Cyclin B1 (#4138), cyclin
D1 (#2978), cyclin A2 (#4656), cyclin E1 (#4129), p-Erk (#4370), Erk (#4695),
p-EGFR (#3777), EGFR (#4267), p-Akt (#4060), Akt (#4691), Rb (#9309), p-Rb
(#9308), RBL1 (#89798), Ubi (#3933), p-FoxM1 (#14655), and FoxM1 (#5436)
were purchased from Cell Signaling Technology. For immunoprecipitation assay,
antibodies were diluted into 50 ng/µL. For immunoblotting assay, antibodies were
diluted into 2.5 ng/µL. For immunoﬂuorescence assay, antibodies were diluted into
25 ng/µL. All immunoblotting original uncropped images were provided as Sup-
plementary materials (Source Data (pptx)) with the manuscript.
Immunoﬂuorescence assay. For immunoﬂuorescence staining, cells were serum
starved overnight before stimulation with 1 ng/mL of EGF and treated with 1 µM
MG-132 for 6 h before ﬁxation. Cells were ﬁxed with 4% paraformaldehyde (PFA)
and permeabilization in 0.2% Triton X-100 (PBS) and followed by anti-FLAG and
Rb antibodies (dilution 1:50) incubation for 18 h at 4 °C. After incubation with
tetramethylrhodamine-conjugated or ﬂuorescein isothiocyanate-conjugated sec-
ondary antibody (dilution 1:100, 25 ng/µL) for 1 h at 25 °C, images were captured
with an Olympus FV1000 2-photon confocal microscope.
Antibody-coupled Dynabeads immunoprecipitation. Cells were infected with
lentiviruses containing pLenti-CMV-puro-3×-FLAG-ΔNLS-DEDD plasmids for
72 h before puromycin (1 μg/mL) treatment for 48 h. The cells were further
cultured for two more doublings. The harvested cells were washed with 1× PBS
and re-suspended in 1:9 ratio of cell mass to extraction buffer (Dynabeads®
Co-Immunoprecipitation (Co-IP) Kit, Thermo Scientiﬁc) with protease inhibi-
tors. The cell lysates were incubated on ice for 30 min and then centrifuged at
2600 × g for 5 min at 4 °C to remove large cell debris and nuclei. BCA
(bicinchoninic acid) assay was used to quantify the protein concentration in the
supernatant. About 5000 μg of protein was incubated with 1 μg of anti-FLAG
antibody (Sigma-Aldrich, F1804)-coupled Dynabeads (10 μg of antibody) on a
roller at 4 °C for 1 h. Another 2000 μg of protein was incubated with 1 mg of
anti-mouse IgG1 (Cell Signaling, 5415S)-coupled Dynabeads (10 μg of antibody)
for non-speciﬁc control immunoprecipitation. One percent of cell lysates were
saved as input control. The Dynabeads® Co-IP complexes were washed with
extraction buffer for three times. The proteins bound to beads were released in
60 μL of elution buffer provided by the kit. The samples were added ﬁve volumes
of cold (−20 °C) acetone overnight at −20 °C.
TNBC in vivo xenograft experiments. All animal experiments were performed in
strict accordance with IACUC guidelines. Rag1 knockout (Rag1−/−) and non-
obese diabetic/severe combined immunodeﬁciency (NOD SCID) mice were
obtained from Taconic Farms (Hudson, NY, USA). For TNBC xenograft experi-
ments, 8-week-old female Rag1−/− mice were transplanted with one million
cancer cells suspended in 0.1 ml of Matrigel mixture (1:1 mixture ratio of Matrigel
and DMEM/F-12 medium without FBS) orthotopically into contralateral sides of
the fourth mammary fat pads of the mice. For TNBC PDXs, 3.5-week-old female
NOD SCID mice have received PDX tumor pieces as previously described41. When
the tumor reached the volume of approximately 100 mm3, the mice were randomly
divided into groups with an even distribution of tumor sizes (10 mice/group). LAP
was given every 48 h at a dose of 100 mg/kg in the vehicle (0.5% hydro-
xypropylmethylcellulose with 0.1% Tween-20) via oral gavage. Abemaciclib was
given every 48 h at a dose of 25 mg/kg in the vehicle (0.5% hydro-
xypropylmethylcellulose with 0.1% Tween-20) via oral gavage. Tumor volume was
calculated as: tumor volume= 1/2 (length × width2). As designated time point post
treatment, tumors were collected and ﬁxed in 4% PFA for 24 h followed by 70%
ethanol for another 24 h before formalin-ﬁxed parafﬁn-embedded embedding for
histology analysis.
Immunohistochemical analysis. PFA-ﬁxed tumor samples were parafﬁn
embedded and cut into 5 μm thin slices and ﬁxed on glass slides. DEDD, Ki-67, or
cleaved caspase-3 were detected by DEDD antibody (Santa Cruz Biotechnology
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#sc-271192), Ki-67 antibody (Ki-67 (D2H10), rabbit monoclonal antibody (IHC-
speciﬁc) (Cell Signaling Technology #9027), or cleaved caspase-3 antibody
(cleaved caspase-3 (Asp175) antibody, Cell Signaling Technology #9661) through
IHC using the Polink-2 Plus HRP Rabbit with DAB Kit (GBI Labs) after 20 min
of antigen retrieval. The stained slides were scanned using the Aperio scanner in
the HCRI Tissue Core Facility (Notre Dame, IN, USA). Images were scored for
the percentage of Ki-67 tumor cell nuclei per total tumor cell nuclei in each
captured ﬁeld using the ImageScope software. For DEDD and cleaved caspase-3,
images were scored as the percentage of positive staining area per captured total
area. All quantiﬁcation was performed in a fashion that was blinded to the
treatment group.
Drug synergism analysis. The raw data for drug synergism analysis were gen-
erated by the MTT assay. The cells were evenly plated 24 h before administration of
drug dosages. Both single and combination treatments were completed in triplicate
at each dosage (4–6 different dosages in a series dilution). Then, the absorbance
reading of each well was calculated as FA by the treatment. The wells treated with
DMSO served as non-affected controls. The wells with medium only served as full-
affected control. The mean FAs at different concentrations were then analyzed by
the CompuSyn software to generate simulation for the drug synergism analysis.
The CI were plotted along with indicated FA for each cell line. CI > 1, antagonism;
CI= 1, addition; CI < 1, synergism.
Bioinformatics and statistical analysis. TCGA breast-invasive carcinoma pro-
visional dataset (1105 samples) was sourced from cBioportal [http://www.
cbioportal.org]. The oncoprint heatmap was generated by including mutations,
putative copy-number changes, and mRNA expression z-scores (RNA-seq V2
RSEM with z threshold ± 2). The survival data were extracted from the same
dataset for Kaplan–Meier plot in R using “Survival” and “Survminer” packages.
The boxplot of the TCGA segmented copy-number changes without germline
CNV (n= 1099) was generated using the University of California, Santa Cruz
(UCSC) Cancer Browser. Gene expression data of commonly used cells lines were
extracted from Broad Institute Cancer Cell Line Encyclopedia (CCLE). The heat-
map of relative gene expression was generated in R using pHeatmap package.
RNA-seq proﬁling of DEDD knockdown cells was conducted by standard Illumina
TruSeq library preparation followed by Illumina sequencing using miSeq. The
differential gene expression analysis was performed using DE-seq2 package. An
adjusted P value of <0.05 was considered statistically signiﬁcant. We performed
GSEA analysis using GenePattern interface [http://www.broadinstitute.org/gsea/]
using C6 v5.2 symbol (oncogenic signature) sub-datasets. Network analysis was
conducted through the web-based bioinformatics package NetworkAnalyst
[https://www.networkanalyst.ca/]-based on recommended protocol. All quantita-
tive data were analyzed and plotted using the GraphPad Prism software. P values
were generated using either two-sided t test or Fisher’s exact test, or one-way
ANOVA test.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All sequencing data that support the ﬁndings of this study have been deposited in the
National Center for Biotechnology Information Gene Expression Omnibus (GEO) and
are accessible through the GEO Series accession number GSE131303. All other relevant
data are available from the corresponding author on request.
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